Jefferies analyst Brian Tanquilut raised his price target for HCA Healthcare to $155 saying the stock "still has room to run" despite the year-to-date rally. HCA is well positioned to deliver organic revenue and EBITDA growth acceleration in the next few years, as it benefits from economic/population growth in its markets, strategic investments and selective acquisitions, Tanquilut tells investors in a research note. Further, the analyst believes "easy" Q3 comps and the tailwind from an upcoming Medicare rate bump "should provide incremental stock momentum." He keeps a Buy rating on the shares.